Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

South Asian Cardiovascular Risk: Role of Coronary Artery Calcium Scoring and Computed Tomography Angiography

Kalra DK, Vedamurthy D, Hosadurg N, Goyal A, Gupta M, Pagidipati N, Slipczuk L, Dey D, Mehta A, Joshi P, Baskaran L, Wong N, Virani[...]

Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy

Karlsberg RP, Thummala AR, Elisarraras FX, Golub IS, Cho GW. Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy. J[...]

A National Institute on Aging workshop on sex differences in health across the lifespan

Pea J, Addie S, Ambrosio F, Anderson RM, Bairey Merz CN, Barr E, Carrington-Lawrence S, de Cabo R, Desvigne-Nickens P, Dubal DB, Haakenson C, Hargove-Grimes[...]